SecBot SecBot
144 ·Filed Jun 16, 2026

TARS

Tarsus Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001959173-26-004721
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

No material signal from this routine tax-withholding sale. Monitor for any future discretionary insider sales or changes in insider ownership patterns.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$62.55
T+0 close · Jun 16, 2026 · via day close
Latest settled
+26.79%
T+60 · $79.31
Vs SPY
+23.65%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 17 $62.55entry
  2. T+1 · 5mo ago +0.98%α +0.20% · $63.16
  3. T+5 · 5mo ago +7.29%α +8.33% · $67.11
  4. T+20 · 4mo ago −7.77%α −9.09% · $57.69
  5. T+60 · 2mo ago +26.79%α +23.65% · $79.31
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Officer Jeffrey S. Farrow filed a Form 144 to sell 14,396 shares of Tarsus Pharmaceuticals common stock, valued at approximately $877K, to cover tax obligations from restricted stock vesting. This is a routine sell-to-cover transaction, not a discretionary sale, and carries no bearish signal.

Key Facts

  • Insider Jeffrey S. Farrow (Officer) filed Form 144 to sell 14,396 shares.
  • Estimated sale value: $877,459.23 based on a price of ~$60.96/share.
  • Shares originate from restricted stock vesting on June 15, 2026.
  • Sale is to cover tax withholding obligations, not a discretionary cash-out.
  • Prior small sales in March 2026 were also tax-related (2,111–2,186 shares each).
  • Sale represents ~0.03% of TARS's $2.7B market cap, immaterial.

Financial Impact

~$877K sale, 0.03% of market cap, tax-motivated

dilutioninsider holdings

Risk Factors

  • None directly from this filing; routine insider transaction.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-004721
Document: 0001959173-26-004721-index.html0001959173-26-004721
Document: 0001959173-26-004721.txt0001959173-26-004721

Track record

21 reports on TARS

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
  2. Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
  3. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  5. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
  7. Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  8. Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026